Table 1.
Case series of women (n > 20) with breast cancer receiving chemotherapy during pregnancy.
| Study | Number of patients | Regimen | Gestational age at starting chemotherapy | Gestational age at delivery | Birth weight | Congenital anomalies |
|---|---|---|---|---|---|---|
| Cardonick et al. [2010] | 130 | AC (69%), FAC, FEC, A single agent, V single agent taxane also given in 11 cases | Mean 20.4 ± 5.4 wks | Mean 35.8 ± 1.9 wks | Mean 2836 ± 1075 g | Four cases (3.8%): – pyloric stenosis – asymptomatic pulmonary artery fistula – holoprosencephalopathy – talipes and haemangioma |
| Hahn et al. [2006] | 57 | FAC | Median 23 wks (range 11–34) | Median 37 wks (range 29–42) | Median 2890 g (range 1389–3977) | Three cases (5.3%): – Down’s syndrome – ureteral reflux – club foot |
| Peccatori et al. [2009] | 20 | Weekly epirubicin 35 mg/m2 | Median 19 wks (range, 16–30) | Median 35 wks (range, 28–40) | Not published | One case (5%): – polycystic kidney |
| Azim et al. [2008] | 26 | Anthracycline- based (E = 23, A = 3) | Second trimester in all patients | Median 35 wks (28–40) | Not published | One case (3.8%): – polycystic kidney |
| Ring et al. [2005b] | 28 | AC (N = 11), EC (N = 5), CMF (N = 12) | Median 20 wks (range 15–33) | Median 37 wks (range, 30–40) | Median 3000 g (range 1400–3500) | Nil |
A, adriamycin; C, cyclophosphamide; F, 5-flurouracil; E, epirubicin; V, vinorelbine; M, methotrexate; wks, weeks.